BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage firm creating a brand new class of genetic medicines for the remedy of cardiovascular ailments, right this moment introduced that as of December 31, 2024, the corporate has granted inventory grants to a brand new worker. , pursuant to the Firm’s 2024 Inventory Incentive Plan, as a big incentive to such new worker coming into employment with the Firm pursuant to Nasdaq. Registration Rule 5635(c)(4).
The worker acquired a complete of 5,330 restricted inventory items (RSUs). RSUs will vest in equal annual installments on the primary 4 anniversaries of January 1, 2025, topic to such worker’s continued service with the Firm on every such vesting date.
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage firm creating a brand new class of genetic medicines for heart problems with the potential to rework power care remedy into single-treatment gene-edited medicines . The Firm’s lead applications “VERVE-101, VERVE-102 and VERVE-201” goal genes which were extensively validated as targets for decreasing low-density lipoprotein ldl cholesterol (LDL-C), a root reason for illness. atherosclerotic heart problems (ASCVD). . VERVE-101 and VERVE-102 are designed to completely deactivate the PCSK9 gene within the liver and are being developed initially for the remedy of heterozygous familial hypercholesterolemia (HeFH) and, finally, to deal with sufferers with established ASCVD who proceed to be affected by excessive LDL-C ranges. . VERVE-201 is designed to completely deactivate the ANGPTL3 gene within the liver and is initially being developed for the remedy of refractory hypercholesterolemia, wherein sufferers nonetheless have elevated LDL-C regardless of remedy with maximally tolerated normal therapies , and for homozygous familial hypercholesterolemia (HoFH). For extra data, please go to www.VerveTx.com.
Investor contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
Supply: Verve Therapeutics
#Verve #Therapeutics #Proclaims #Incentive #Grants #Nasdaq #Itemizing #Rule #5635c4 #Investing.com , #Gossip247
,
